Clearing a way through the CRISPR patent jungle

The revocation of the Broad Institute’s patent EP2771468, reported and discussed here, marks the latest major development in a series of patent battles over the revolutionary and highly lucrative CRISPR/Cas 9 technology (and other gene-editing technologies) in the US and Europe.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?

13 July 2018 As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.

Europe

CRISPR in Europe: the patent landscape for 2018

30 November 2017 The Broad Institute of MIT and Harvard may lose a substantial number of European patent claims covering CRISPR/Cas9, but it has at least one trump card to play before we get to that stage, one European patent attorney has told LSIPR.

Americas

Broad Institute takes three lines of attack in CRISPR appeal filing

26 October 2017 The Broad Institute of Harvard and MIT has adopted three major arguments in its response to the University of California, Berkeley’s appeal against a patent finding on the CRISPR technology.